Picton Mahoney Asset Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Picton Mahoney Asset Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150,000	Closed	-$1.51M	–	728
2022 Q4	$1.51M	Hold	150,000	–	–	0.07%	338
2022 Q3	$1.49M	Hold	150,000	–	–	0.05%	389
2022 Q2	$1.49M	Hold	150,000	–	–	0.06%	470
2022 Q1	$1.48M	Hold	150,000	–	–	0.05%	487
2021 Q4	$1.48M	Hold	150,000	–	–	0.04%	489
2021 Q3	$1.46M	Buy	+150,000	New	+$1.45M	0.05%	451

Picton Mahoney Asset Management's BIOT Position: Q1 2023 in Review

Picton Mahoney Asset Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 150,000 shares — an estimated $1.51M sold.

Picton Mahoney Asset Management first reported a position in BIOT in Q3 2021 and held it in 6 quarters. The position peaked at $1.51M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

Picton Mahoney Asset Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
Picton Mahoney Asset Management sold 150,000 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $1.51M.
Picton Mahoney Asset Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q3 2021 and held it in 6 quarters.
Picton Mahoney Asset Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $1.51M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q1 2023, filed 8 May 2023.